Nyxoah Delivers €7.7M in Preliminary Q2 Revenue as CMS Proposes 12–15% Reimbursement Boost
NYXH sits 33% above its 52-week low of $1.26.
Summary
Preliminary Q2 revenue of €7.7M (up 21% sequentially) was accompanied by a proposed CMS reimbursement increase of 12–15% for the Genio procedure and disclosure of a new 14.55% stake by Orin Hirchman. Full-year guidance is reiterated, and cash stands at €97.8M.
Key Events · Earnings and Guidance · NYXH
-
Preliminary Q2 Revenue of €7.7M
Global net revenue reached approximately €7.7 million, a 21% sequential increase over Q1 2026, with U.S. revenue of €5.2 million (22% sequential growth).
-
CMS Proposes 12–15% Reimbursement Increase
CMS proposed raising hospital outpatient reimbursement for the Genio procedure from $31,526 to $35,414 (12% increase) and ASC reimbursement from $27,563 to $31,722 (15% increase).
-
Strong U.S. Commercial Momentum
180 high-volume accounts are now active, 262 surgeons trained, and 427 patients submitted under prior authorization entering Q3.
-
Cash Position of €97.8M After $110M Financing
As of June 30, 2026, cash and equivalents were approximately €97.8 million, following the $95 million equity offering and $15 million EIB loan secured in Q2.
Analysis · NYXH · Industrial Applications And Services
Preliminary Q2 revenue reached €7.7 million, a 21% sequential gain fueled by accelerating U.S. adoption—180 active accounts and 427 patients in the prior-authorization pipeline. The economic case for providers strengthens materially under a CMS proposal to lift hospital and ASC reimbursement for the Genio procedure by 12% and 15%, respectively, which could further accelerate commercial uptake. With €97.8 million in cash following the recent $110 million financing package, the near-term liquidity overhang is removed, and full-year guidance of €36–40 million is reiterated. The filing also reveals that Orin Hirchman, through AIGH Capital, has built a 14.55% stake, signaling institutional conviction, while Resmed's passive stake fell below 3%.
At the time of this filing, NYXH was trading at $1.67 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $166.9M. The 52-week trading range was $1.26 to $8.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.